Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management

Overview

Journal Endocrinol Metab (Seoul)

Specialty Endocrinology

Date 2024 Apr 16

PMID 38626909

Authors

Jang Won Son

Soo Lim

Affiliations

Soon will be listed here.

Abstract

Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein-coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1-glucagon and GIP-GLP-1-glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.

Citing Articles

Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.

Alenezi B, Elfezzani N, Uddin R, Patel H, Chester S, Abdelmaksoud A J Clin Med. 2024; 13(16).

PMID: 39201039 PMC: 11355112. DOI: 10.3390/jcm13164896.

Diabetes and Osteoarthritis: Exploring the Interactions and Therapeutic Implications of Insulin, Metformin, and GLP-1-Based Interventions.

Halabitska I, Babinets L, Oksenych V, Kamyshnyi O Biomedicines. 2024; 12(8).

PMID: 39200096 PMC: 11351146. DOI: 10.3390/biomedicines12081630.

Why you should not skip tailored exercise interventions when using incretin mimetics for weight loss.

Gross K, Brinkmann C Front Endocrinol (Lausanne). 2024; 15:1449653.

PMID: 39109078 PMC: 11300307. DOI: 10.3389/fendo.2024.1449653.

References

Bluher M, Rosenstock J, Hoefler J, Manuel R, Hennige A . Dose-response effects on HbA and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2023; 67(3):470-482. PMC: 10844353. DOI: 10.1007/s00125-023-06053-9. View

Nauck M, Muller T . Incretin hormones and type 2 diabetes. Diabetologia. 2023; 66(10):1780-1795. PMC: 10474001. DOI: 10.1007/s00125-023-05956-x. View

Oury C, Marechal P, Donis N, Hulin A, Hego A, Tridetti J . Dexfenfluramine and Pergolide Cause Heart Valve Disease via Valve Metabolic Reprogramming and Ongoing Matrix Remodeling. Int J Mol Sci. 2020; 21(11). PMC: 7312197. DOI: 10.3390/ijms21114003. View

Ban K, Noyan-Ashraf M, Hoefer J, Bolz S, Drucker D, Husain M . Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008; 117(18):2340-50. DOI: 10.1161/CIRCULATIONAHA.107.739938. View

Sattar N, Lee M, Kristensen S, Branch K, Del Prato S, Khurmi N . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021; 9(10):653-662. DOI: 10.1016/S2213-8587(21)00203-5. View

Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G . Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023; 29(11):2909-2918. PMC: 10667099. DOI: 10.1038/s41591-023-02597-w. View

Becerril S, Fruhbeck G . Cagrilintide plus semaglutide for obesity management. Lancet. 2021; 397(10286):1687-1689. DOI: 10.1016/S0140-6736(21)00944-2. View

Kadowaki T, Isendahl J, Khalid U, Lee S, Nishida T, Ogawa W . Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022; 10(3):193-206. DOI: 10.1016/S2213-8587(22)00008-0. View

Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X. View

10.

Frias J, Davies M, Rosenstock J, Perez Manghi F, Lando L, Bergman B . Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021; 385(6):503-515. DOI: 10.1056/NEJMoa2107519. View

11.

Ussher J, Drucker D . Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023; 20(7):463-474. DOI: 10.1038/s41569-023-00849-3. View

12.

Parkes D, Mace K, Trautmann M . Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1. Expert Opin Drug Discov. 2012; 8(2):219-44. DOI: 10.1517/17460441.2013.741580. View

13.

Wadden T, Hollander P, Klein S, Niswender K, Woo V, Hale P . Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes (Lond). 2013; 37(11):1443-51. DOI: 10.1038/ijo.2013.120. View

14.

Hales C, Carroll M, Fryar C, Ogden C . Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief. 2020; (360):1-8. View

15.

Gallo M . Thyroid safety in patients treated with liraglutide. J Endocrinol Invest. 2013; 36(2):140-5. DOI: 10.1007/BF03346749. View

16.

Dai C, Hang Y, Shostak A, Poffenberger G, Hart N, Prasad N . Age-dependent human β cell proliferation induced by glucagon-like peptide 1 and calcineurin signaling. J Clin Invest. 2017; 127(10):3835-3844. PMC: 5617654. DOI: 10.1172/JCI91761. View

17.

Farooqi S . Genetic, molecular and physiological mechanisms involved in human obesity: Society for Endocrinology Medal Lecture 2012. Clin Endocrinol (Oxf). 2014; 82(1):23-8. DOI: 10.1111/cen.12588. View

18.

Loffler M, Betz M, Blondin D, Augustin R, Sharma A, Tseng Y . Challenges in tackling energy expenditure as obesity therapy: From preclinical models to clinical application. Mol Metab. 2021; 51:101237. PMC: 8122111. DOI: 10.1016/j.molmet.2021.101237. View

19.

Ahmad E, Lim S, Lamptey R, Webb D, Davies M . Type 2 diabetes. Lancet. 2022; 400(10365):1803-1820. DOI: 10.1016/S0140-6736(22)01655-5. View

20.

Younk L, Mikeladze M, Davis S . Pramlintide and the treatment of diabetes: a review of the data since its introduction. Expert Opin Pharmacother. 2011; 12(9):1439-51. DOI: 10.1517/14656566.2011.581663. View